Expert: Stephen Meyer

With the spread of COVID-19 across the globe, life science supply chains are managing through depleted workforces and transportation restrictions. Gartner interviewed supply chain leaders in pharmaceutical and medical device manufacturing to collect the best practices in managing through this disruption. Nearly all interviewees singled out the reduction of air freight and congestion in ports as the single biggest supply chain impact. While demand spikes directly related to the outbreak are obvious, the clear message from most interviewees was that swings in secondary demand caught them off guard. To address these impacts, tactical management and flexibility are key. 

This research advises supply chain leaders in life science on the specific actions they can take to ensure products can still be produced and shipped with minimal disruption.

Fill out the form to download the full research.